⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2948824 | 1.00 | — | — | |
| SCHEMBL2948821 | 1.00 | — | — | |
| SCHEMBL1254922 | 0.84 | ALDH1A1 (0.59) | — | |
| SCHEMBL17183611 | 0.81 | — | — | |
| SCHEMBL212884 | 0.78 | RBBP9 (0.55) | — | |
| SCHEMBL213922 | 0.75 | RBBP9 (0.52) | — | |
| SCHEMBL8213363 | 0.75 | — | — | |
| SCHEMBL10173369 | 0.74 | — | — | |
| SCHEMBL201473 | 0.74 | — | — | |
| SCHEMBL2707330 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763623-B2 | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | SCHERING CORPORATION (US) | 2010-07-27 | — | — | US | disclosed |
| US-7763623-B2 | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | SCHERING CORPORATION (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070173495-A1 | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | SCHERING CORPORATION | 2007-07-26 | — | — | US | disclosed |
| US-20070173495-A1 | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | SCHERING CORPORATION | 2007-07-26 | — | — | US | disclosed |